These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 16616331)
1. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Liu Y; Cheney MD; Gaudet JJ; Chruszcz M; Lukasik SM; Sugiyama D; Lary J; Cole J; Dauter Z; Minor W; Speck NA; Bushweller JH Cancer Cell; 2006 Apr; 9(4):249-60. PubMed ID: 16616331 [TBL] [Abstract][Full Text] [Related]
2. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037 [TBL] [Abstract][Full Text] [Related]
3. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity. Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017 [TBL] [Abstract][Full Text] [Related]
4. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359 [TBL] [Abstract][Full Text] [Related]
5. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation. Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665 [TBL] [Abstract][Full Text] [Related]
8. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Liu Y; Chen W; Gaudet J; Cheney MD; Roudaia L; Cierpicki T; Klet RC; Hartman K; Laue TM; Speck NA; Bushweller JH Cancer Cell; 2007 Jun; 11(6):483-97. PubMed ID: 17560331 [TBL] [Abstract][Full Text] [Related]
9. Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor beta. Qiu J; Wong J; Tweardy DJ; Dong S Oncogene; 2006 Jun; 25(28):3982-93. PubMed ID: 16474840 [TBL] [Abstract][Full Text] [Related]
10. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro. Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925 [TBL] [Abstract][Full Text] [Related]
11. The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain. Plevin MJ; Zhang J; Guo C; Roeder RG; Ikura M Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10242-10247. PubMed ID: 16803958 [TBL] [Abstract][Full Text] [Related]
12. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion. Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631 [TBL] [Abstract][Full Text] [Related]
13. CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Roudaia L; Cheney MD; Manuylova E; Chen W; Morrow M; Park S; Lee CT; Kaur P; Williams O; Bushweller JH; Speck NA Blood; 2009 Mar; 113(13):3070-9. PubMed ID: 19179469 [TBL] [Abstract][Full Text] [Related]
14. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells. Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927 [TBL] [Abstract][Full Text] [Related]
15. A distinct epigenetic signature at targets of a leukemia protein. Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773 [TBL] [Abstract][Full Text] [Related]
16. Cooperative function of Aml1-ETO corepressor recruitment domains in the expansion of primary bone marrow cells. Hug BA; Lee SY; Kinsler EL; Zhang J; Lazar MA Cancer Res; 2002 May; 62(10):2906-12. PubMed ID: 12019171 [TBL] [Abstract][Full Text] [Related]
17. AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain. Wei H; Liu X; Xiong X; Wang Y; Rao Q; Wang M; Wang J FEBS Lett; 2008 Jun; 582(15):2167-72. PubMed ID: 18519037 [TBL] [Abstract][Full Text] [Related]
18. The role of CBFbeta in AML1-ETO's activity. Park S; Speck NA; Bushweller JH Blood; 2009 Sep; 114(13):2849-50. PubMed ID: 19779050 [No Abstract] [Full Text] [Related]
19. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326 [TBL] [Abstract][Full Text] [Related]
20. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]